Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Effects of Selenium on Short-Term Control of Hyperthyroidism due to Graves’ Disease Treated With Methimazole: Results of a Randomized Clinical Trial
source: Journal of Endocrinological Investigation
authors: Leo M, Bartalena L, Rotondo Dottore G, Piantanida E, Premoli P, Ionni I, Di Cera M, Masiello E, Sassi L, Tanda ML, Latrofa F, Vitti P, Marcocci C, Marinò Msummary/abstract:
In spite of previous conflicting results, an adjuvant role of selenium in the treatment of Graves’ disease (GD) hyperthyroidism has been proposed. To address this issue, a randomized clinical trial was carried out aimed at investigating whether selenium is beneficial on the short-term control of GD hyperthyroidism treated with methimazole (MMI).
Thirty newly diagnosed hyperthyroid GD patients were randomly assigned to treatment with: (i) MMI or (ii) MMI plus selenium. Primary outcomes were: control of hyperthyroidism and clinical and biochemical manifestations of hyperthyroidism [heart rate, cholesterol, sex hormone-binding globulin (SHBG), hyperthyroidism symptoms] at 90 days.
Baseline features of the two groups did not differ. Serum selenium at baseline was similar in the two groups and within the recommended range to define selenium sufficiency. Selenium increased with treatment in the MMI-selenium group and became significantly higher than in the MMI group. Serum malondialdehyde, a marker of oxidative stress, was similar in the two groups and decreased significantly with treatment, with no difference between groups. Administration of MMI was followed by a reduction of FT3 and FT4, with no difference between groups. Heart rate, SHBG and symptoms of hyperthyroidism decreased, whereas total cholesterol increased in both groups with no difference between groups.
Our study, carried out in a selenium-sufficient cohort of GD patients, failed to show an adjuvant role of selenium in the short-term control of hyperthyroidism. However, selenium might be beneficial in patients from selenium-deficient areas, as well as in the long-term outcome of antithyroid treatment.
Subclinical Hypothyroidism After 131I-Treatment of Graves’ Disease: A Risk Factor for Depression?Objectives: Although it is well accepte...
Methimazole for Graves’ Disease Linked to Acute PancreatitisThe treatment of Graves' disease with th...
National Trends in Incidence, Mortality, and Clinical Outcomes of Patients Hospitalized for Thyrotoxicosis With and ...Background: Current evidence on the i...
Thyroid-Associated Ophthalmopathy After Treatment for Graves’ Hyperthyroidism With Antithyroid Drugs or Iodine...Context: Previous randomized trials hav...
Hyperthyroidism OverviewHyperthyroidism is known as overactive t...
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 StudyResults from the phase 3 OPTIC study sho...
Effect of Long-Term Continuous Methimazole Treatment of Hyperthyroidism: Comparison With RadioiodineObjective: To investigate the long-term...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.